I am a
Home I AM A Search Login

Papers of the Week

2022 Aug 04

Clin Gastroenterol Hepatol

Safety and sustained efficacy of the farnesoid X receptor (FXR) agonist cilofexor over a 96-week open-label extension in patients with PSC.


Trauner M, Bowlus CL, Gulamhusein A, Hameed B, Caldwell SH, Shiffman ML, Landis C, Muir AJ, Billin A, Xu J, Liu X, Lu X, Chung C, Myers RP, Kowdley KV
Clin Gastroenterol Hepatol. 2022 Aug 04.
PMID: 35934287.


Primary sclerosing cholangitis (PSC) is a major unmet medical need in clinical hepatology. Cilofexor is a non-steroidal FXR agonist being evaluated for the treatment of PSC. Here, we describe the safety and preliminary efficacy of cilofexor in a 96-week, open-label extension (OLE) of a phase 2 trial.